CoChat
Sign Up
Cited by 47

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

miR-128 Regulates Tumor Cell CD47 Expression and Promotes Anti-tumor Immunity in Pancreatic Cancer

Xi, Qing, Chen, Ying, Yang, Guang-Ze, Zhang, Jie-You, Zhang, Li-Juan, Guo, Xiang-Dong, Zhao, Jing-Yi, Xue, Zhen-Yi, Li, Yan, Zhang, Rongxin·2020·Frontiers in Immunology
DOI 10.3389/fimmu.2020.00890PMC PMC7267029
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2020.00890

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 3 references

Research works printed but not linked: 44

  1. Kleeff, 2016, Pancreatic cancer, Nat Rev Dis Primers., 2, 16022, 10.1038/nrdp.2016.22 · DOI · Paper page
  2. Siegel, 2017, Cancer statistics, 2017, CA Cancer J Clin., 67, 7, 10.3322/caac.21387 · DOI · Paper page
  3. Rahib, 2014, Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res., 74, 2913, 10.1158/0008-5472.CAN-14-0155 · DOI · Paper page
  4. Sharma, 2015, The future of immune checkpoint therapy, Science., 348, 56, 10.1126/science.aaa8172 · DOI · Paper page
  5. Brown, 2001, Integrin-associated protein (CD47) and its ligands, Trends Cell Biol., 11, 130, 10.1016/S0962-8924(00)01906-1 · DOI
  6. Jaiswal, 2009, CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis, Cell., 138, 271, 10.1016/j.cell.2009.05.046 · DOI
  7. Willingham, 2012, The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors, Proc Natl Acad Sci U S A., 109, 6662, 10.1073/pnas.1121623109 · DOI
  8. Michaels, 2018, CD47 blockade as an adjuvant immunotherapy for resectable pancreatic cancer, Clin Cancer Res., 24, 1415, 10.1158/1078-0432.CCR-17-2283 · DOI
  9. Murata, 2018, CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy, Cancer Sci., 109, 2349, 10.1111/cas.13663 · DOI
  10. Matlung, 2017, The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer, Immunol Rev., 276, 145, 10.1111/imr.12527 · DOI
  11. Weiskopf, 2017, Cancer immunotherapy targeting the CD47/SIRPα axis, Eur J Cancer., 76, 100, 10.1016/j.ejca.2017.02.013 · DOI
  12. Liu, 2015, CD47 blockade triggers T cell-mediated destruction of immunogenic tumors, Nat Med., 21, 1209, 10.1038/nm.3931 · DOI
  13. Nieto, 2016, EMT: 2016, Cell., 166, 21, 10.1016/j.cell.2016.06.028 · DOI · Paper page
  14. Puisieux, 2014, Oncogenic roles of EMT-inducing transcription factors, Nat Cell Biol., 16, 488, 10.1038/ncb2976 · DOI
  15. Caramel, 2018, Pleiotropic roles for ZEB1 in cancer, Cancer Res., 78, 30, 10.1158/0008-5472.CAN-17-2476 · DOI
  16. Krebs, 2017, The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer, Nat Cell Biol., 19, 518, 10.1038/ncb3513 · DOI
  17. Noman, 2018, CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT, Oncoimmunology, 7, e1345415, 10.1080/2162402X.2017.1345415 · DOI
  18. Yang, 2015, miR-192 suppresses leptomeningeal dissemination of medulloblastoma by modulating cell proliferation and anchoring through the regulation of DHFR. integrins, and CD47, Oncotarget., 6, 43712, 10.18632/oncotarget.6227 · DOI
  19. Huang, 2018, MIR-708 promotes phagocytosis to eradicate T-ALL cells by targeting CD47, Mol Cancer., 17, 12, 10.1186/s12943-018-0768-2 · DOI
  20. Bruno, 2011, Identification of a microRNA that activates gene expression by repressing nonsense-mediated RNA decay, Mol Cell., 42, 500, 10.1016/j.molcel.2011.04.018 · DOI
  21. Hsu, 2006, miRNAMap: genomic maps of microRNA genes and their target genes in mammalian genomes, Nucleic Acids Res., 34, D135, 10.1093/nar/gkj135 · DOI
  22. Woo, 2012, Regulation of colony stimulating factor-1 expression and ovarian cancer cell behavior in vitro by miR-128 and miR-152, Mol Cancer., 11, 58, 10.1186/1476-4598-11-58 · DOI
  23. Lu, 2017, Posttranscriptional regulation of Galectin-3 by miR-128 contributes to colorectal cancer progression, Oncotarget, 8, 15242, 10.18632/oncotarget.14839 · DOI
  24. Xiao, 2018, MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer, BJS., 105, 75, 10.1002/bjs.10646 · DOI
  25. Corbett, 1984, Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice, Cancer Res., 44, 717
  26. Vasaikar, 2018, LinkedOmics: analyzing multi-omics data within and across 32 cancer types, Nucleic Acids Res, 46, D956, 10.1093/nar/gkx1090 · DOI
  27. Subramani, 2015, Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis (Review), Int J Oncol., 47, 1203, 10.3892/ijo.2015.3129 · DOI
  28. Li, 2016, MicroRNA targeted therapeutic approach for pancreatic cancer, Int J Biol Sci., 12, 326, 10.7150/ijbs.15017 · DOI
  29. Frampton, 2015, Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression, Lancet., 385, S37, 10.1016/S0140-6736(15)60352-X · DOI
  30. Sharpe, 2017, Introduction to checkpoint inhibitors and cancer immunotherapy, Immunol Rev., 276, 5, 10.1111/imr.12531 · DOI
  31. Cioffi, 2017, The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1, Oncotarget., 8, 21609, 10.18632/oncotarget.15450 · DOI
  32. Mari, 2018, microRNA 125a regulates MHC-I expression on esophageal adenocarcinoma cells, associated with suppression of antitumor immune response and poor outcomes of patients, Gastroenterology., 155, 784, 10.1053/j.gastro.2018.06.030 · DOI
  33. Zhao, 2011, CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction, Proc Natl Acad Sci U S A., 108, 18342, 10.1073/pnas.1106550108 · DOI
  34. Liu, 2015, Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential, PLoS One., 10, e0137345, 10.1371/journal.pone.0137345 · DOI
  35. Brabletz, 2010, The ZEB/miR-200 feedback loop–a motor of cellular plasticity in development and cancer?, EMBO Rep., 11, 670, 10.1038/embor.2010.117 · DOI
  36. Vandewalle, 2009, The role of the ZEB family of transcription factors in development and disease, Cell Mol Life Sci., 66, 773, 10.1007/s00018-008-8465-8 · DOI
  37. Burk, 2008, A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells, EMBO Rep., 9, 582, 10.1038/embor.2008.74 · DOI
  38. Sun, 2015, miR-128 modulates chemosensitivity and invasion of prostate cancer cells through targeting ZEB1, Jpn J Clin Oncol., 45, 474, 10.1093/jjco/hyv027 · DOI
  39. Zhao, 2018, Tumor suppressor miR-128-3p inhibits metastasis and epithelial-mesenchymal transition by targeting ZEB1 in esophageal squamous-cell cancer, Acta Biochim Biophys Sin., 50, 171, 10.1093/abbs/gmx132 · DOI
  40. Xu, 2017, Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein α signaling, Immunity., 47, 363, 10.1016/j.immuni.2017.07.016 · DOI
  41. Terabe, 2008, The role of NKT cells in tumor immunity, Adv Cancer Res., 101, 277, 10.1016/S0065-230X(08)00408-9 · DOI
  42. Bendelac, 2007, The biology of NKT cells, Annu Rev Immunol., 25, 297, 10.1146/annurev.immunol.25.022106.141711 · DOI
  43. Brennan, 2013, Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions, Nat Rev Immunol., 13, 101, 10.1038/nri3369 · DOI
  44. Brigl, 2003, Mechanism of CD1d-restricted natural killer T cell activation during microbial infection, Nat Immunol., 4, 1230, 10.1038/ni1002 · DOI

Cited by

Sorted by citations

See all 47

Metadata

Authors
Xi, Q., Chen, Y., Yang, G.-Z., Zhang, J.-Y., Zhang, L.-J., Guo, X.-D., Zhao, J.-Y., Xue, Z.-Y., Li, Y., & Zhang, R.
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2020-05-27
Volume
11
ISSN
1664-3224
DOI
10.3389/fimmu.2020.00890
PMC
PMC7267029
Cited by
47
References
3
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
National Natural Science Foundation of China

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review